Browse studies

Find your next paid study

77 recruiting studies matching your filters

A Multicenter Open-Label Interventional Biomarker Study of Lutikizumab in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa or Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such …

Hidradenitis SuppurativaAtopic Dermatitis

Estimated

~$75 – $3,000

Actual pay is set by the research site.

AbbVieNCT06524635

Phase 1

Feasibility and Tolerability of Silverlon® for Definitive Head and Neck Patients With Tracheostomies

The purpose of this study is to determine if prophylactic silver-nylon burn dressing Silverlon® prevents a severe skin reaction under tracheostomy collars. It …

Head and Neck CancerRadiation Dermatitis AcuteRadiation Treatment

Estimated

~$150 – $3,000

Actual pay is set by the research site.

State University of New York - Upstate Medical UniversityNCT07856732

Phase 4

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

Atopic DermatitisSleep Disturbance

Estimated

~$25 – $1,000

Actual pay is set by the research site.

Northwestern UniversityNCT05042258

Phase 2

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)

The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pi…

Atopic DermatitisAtopic Dermatitis EczemaEczema+1 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Corvus Pharmaceuticals, Inc.NCT07441395

Phase 3

A Phase 3 Multi-center Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children (Age 2 to <12 Years) and Infants (Age 6 Months to <2 Years) With Moderate-to-severe Atopic Dermatitis. The Trial is Randomized, Double-blind, Placebo-controlled, and Parallel-group for Children (Age 2 to <12 Years) and Open-label and Single-group for Infants (Age 6 Months to <2 Years)

The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticostero…

Atopic Dermatitis

Estimated

~$50 – $2,100

Actual pay is set by the research site.

LEO PharmaNCT06311682

Observational

Ultrasonic Perfusion Imaging for Monitoring Mastectomy Skin Microcirculation in Post-mastectomy Irradiated Patients Before and After Autologous Fat Transfer

The purpose of this study is to evaluate post-mastectomy breast skin blood supply (perfusion) after radiation therapy, and before and after fat grafting to the…

Breast ReconstructionRadiation DermatitisRadiation Fibrosis+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT04992650

Studies of Skin Microflora in Healthy Individuals and Atopic Dermatitis Patients

This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze he…

EczemaAtopic Dermatitis

Estimated

~$10 – $675

Actual pay is set by the research site.

National Human Genome Research Institute (NHGRI)NCT00605878

Phase 4

A Phase 4, Prospective, Multicenter, Single-Arm, Pragmatic Interventional Cohort Study Evaluating Real-World Outcomes and Dosing Patterns of Ebglyss (Lebrikizumab) in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

The goal of this Phase 4 clinical study is to learn how Ebglyss (lebrikizumab) works and how it is dosed in everyday dermatology care for adults and adolescent…

Atopic Dermatitis

Estimated

~$25 – $1,500

Actual pay is set by the research site.

Forefront Dermatology S.CNCT07856134

Phase 3

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to- Severe Atopic Dermatitis

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 year…

Moderate-to-Severe Atopic Dermatitis

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Nektar TherapeuticsNCT07711418

Observational

A Randomized Controlled Trial to Evaluate Wound Complications After Primary Total Hip Arthroplasty Using Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh

The purpose of this study is to document the incidence of allergic contact dermatitis (ACD) to silk fibroin and 2-octyl cyanoacrylate mesh dressings, to docume…

Allergic Contact Dermatitis (ACD)

Estimated

~$10 – $750

Actual pay is set by the research site.

The University of Texas Health Science Center, HoustonNCT07868900

Phase 1

A PHASE 1, FIRST IN HUMAN, RANDOMIZED, DOUBLE-BLIND, SPONSOROPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07832837 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy particip…

Healthy ParticipantsAtopic Dermatitis

Estimated

~$500 – $11,250

Actual pay is set by the research site.

PfizerNCT06564389

Phase 4

Molecular Signatures of Cutaneous Dupilumab Response

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Atopic Dermatitis

Estimated

~$25 – $900

Actual pay is set by the research site.

University of California, San FranciscoNCT05858619